Streetbeat News

Stock Prices

PH

Parker Hannifin (NYSE:PH) has significantly outperformed the market over the past 5 years, with an average annual return of 26.53%. A $100 investment in PH 5 years ago would now be worth $318.88, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 9:00 pm

BBIO

BridgeBio announced results from its Phase 1/2 trial of the investigational gene therapy BBP-631 for Congenital Adrenal Hyperplasia. The trial showed increased cortisol production in higher dose cohorts, with mild to moderate adverse events. However, the results did not justify further capital investment, leading to a $50M budget reduction for gene therapy.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 8:49 pm

FTCI

FTC Solar, Inc. (NASDAQ:FTCI) shares surged in after-hours trading following a multi-year agreement with Strata Clean Energy to supply 500 megawatts of solar tracker technology, potentially expanding to over a gigawatt. The first project is expected to start in Q4 2024.

Portfolio Pulse from Erica Kollmann

September 10, 2024 | 8:48 pm

OKTA

Recent options activity for Okta shows a bearish sentiment among large investors, with 66% of trades being bearish. The price range targeted by these trades is between $60 and $77.5. Analysts have mixed ratings on Okta, with price targets ranging from $90 to $110.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:46 pm

GE

Deep-pocketed investors are showing significant interest in GE Aero options, with a mix of bullish and bearish sentiments. The options activity suggests a focus on a price range of $160 to $185. GE Aero's stock is currently trading at $166.98, with an anticipated earnings release in 42 days.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:46 pm

IBM

Recent options trading trends for IBM show a bearish sentiment among financial giants, with 50% of traders making bearish moves. The trading activity includes 18 put options valued at $1.3 million and 10 call options valued at $1.1 million. The predicted price range for IBM is between $170 and $270. Despite a recent price increase to $205.32, IBM's stock may be overbought, and an analyst from UBS maintains a Sell rating with a target price of $145.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 8:46 pm

SPY

USO

The USA API reported a weekly crude oil stock draw of 2.790 million barrels, contrary to the expected build of 0.700 million barrels. This follows a previous draw of 7.400 million barrels.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 8:41 pm

WOOF

Petco Health and Wellness Company, Inc. (NASDAQ:WOOF) reported Q2 results with a loss of nine cents per share, missing estimates. Sales met expectations at $1.52 billion, a 1.99% increase year-over-year. Despite growth in consumables and services, supplies and companion animal business declined. Petco projects Q3 losses and revenue slightly below estimates. Shares rose 2.62% after-hours.

Portfolio Pulse from Erica Kollmann

September 10, 2024 | 8:41 pm

IXHL

Incannex Healthcare Inc. (NASDAQ:IXHL) has secured a $60 million financing agreement with Arena Investors to advance its clinical trials in cannabinoid and psychedelic therapies. The funding includes $10 million in convertible notes and a $50 million equity line of credit. The funds will support trials for treatments targeting obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis.

Portfolio Pulse from Patricio Liddle

September 10, 2024 | 8:40 pm

CNTMF

CRLBF

CURLF

MSOS

The DEA's potential rescheduling of cannabis from Schedule I to Schedule III is a critical issue for investors, with a webinar hosted by Z&A to discuss its implications. The DEA's delay in the final ruling has already impacted cannabis stocks, including a significant drop in the AdvisorShares Pure US Cannabis ETF (MSOS) and other major players.

Portfolio Pulse from Nicolás Jose Rodriguez

September 10, 2024 | 8:37 pm